Author:
Wierdl M,Tsurkan L,Hyatt J L,Edwards C C,Hatfield M J,Morton C L,Houghton P J,Danks M K,Redinbo M R,Potter P M
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Molecular Biology,Molecular Medicine
Reference37 articles.
1. Cashman J, Perroti B, Berkman C, Lin J . Pharmacokinetics and molecular detoxification. Environ Health Perspect 1996; 104: 23–40.
2. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y . Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994; 86: 836–842.
3. Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a Phase I trial in children. J Clin Oncol 1999; 17: 1815–1824.
4. Houghton JA, Cheshire PJ, Hallman JA, Lutz L, Luo X, Li Y et al. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Clin Cancer Res 1996; 2: 107–118.
5. Houghton PJ, Cheshire PJ, Hallman II JD, Lutz L, Friedman HS, Danks MK et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995; 36: 393–403.
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献